back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2026-05-20 13:55 Tx date 2026-05-19 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
46 - Compensation for services
|
$2,500
+16,667 vol $0.15 each |
45,233 | |
| Filed 2026-04-13 12:11 Tx date 2026-02-17 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
46 - Compensation for services
|
$2,500
+16,667 vol $0.15 each |
28,566 | |
| Filed 2025-11-10 15:31 Tx date 2025-10-31 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
46 - Compensation for services
|
$2,498
+11,899 vol $0.21 each |
11,899 | |
| Filed 2025-11-10 15:24 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-04-14 21:32 Tx date 2025-04-08 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+80,000 vol $0.125 each |
80,000 | |
| Filed 2025-04-14 21:31 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-04-14 21:24 Tx date 2025-04-08 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Holder: Abingdon Capital Corporation (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$25,000
+200,000 vol $0.125 each |
200,000 | |
| Filed 2025-04-14 21:23 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Holder: Abingdon Capital Corporation (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-04-14 21:22 Tx date 2025-04-08 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Holder: RBK&C (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$40,375
+323,000 vol $0.125 each |
323,000 | |
| Filed 2025-04-14 20:53 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Holder: RBK&C (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-04-14 20:48 Tx date 2025-04-08 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Holder: Abingdon Capital Corporation (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$25,000
+200,000 vol $0.125 each |
200,000 | |
| Filed 2025-04-14 20:48 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Holder: Abingdon Capital Corporation (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-04-14 20:47 Tx date 2025-04-08 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Holder: RBK&C (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$40,375
+323,000 vol $0.125 each |
323,000 | |
| Filed 2025-04-14 20:46 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Holder: RBK&C (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-04-14 19:54 Tx date 2025-04-08 |
$MRVL
Marvel Biosciences Corp. Formerly Alphanco Venture Corp. |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+80,000 vol $0.125 each |
205,000 | |
| Filed 2024-08-20 11:30 Tx date 2024-08-16 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Holder: Abinvest Corporation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,500
+50,000 vol $0.11 each |
330,000 | |
| Filed 2024-07-31 15:29 Tx date 2024-07-23 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+125,000 vol |
500,000 | |
| Filed 2022-10-04 16:00 Tx date 2022-09-26 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$20,000
+200,000 vol $0.10 each |
375,000 | |
| Filed 2022-07-20 16:20 Tx date 2022-07-18 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Holder: Abinvest Corporation (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$25,000
+250,000 vol $0.10 each |
280,000 | |
| Filed 2022-03-31 12:06 Tx date 2022-03-22 |
$ROZP
Rozdil Capital Corporation |
Johnson, Neil Allan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$12,500
+125,000 vol $0.10 each |
875,000 |